T. Broadhead

发表

The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma

G. Hall, N. Vasudev, D. Cairns, 2011, Archives of Gynecology and Obstetrics.

Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER‐2 cohort study

R. Glasspool, S. Leeson, C. Fotopoulou, 2021, BJOG : an international journal of obstetrics and gynaecology.

Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.

S. Chan, M. Sopwith, R. Coleman, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma

A. Perkins, P. Kenemans, R. Verheijen, 1999, British journal of obstetrics and gynaecology.

Factors Predicting Surgical Effort Using Explainable Artificial Intelligence in Advanced Stage Epithelial Ovarian Cancer

G. Theophilou, R. Hutson, D. Nugent, 2022, Cancers.

Integrated eicosanoid lipidomics and gene expression reveal decreased prostaglandin catabolism and increased 5‐lipoxygenase expression in aggressive subtypes of endometrial cancer

K. Massey, A. Nicolaou, M. Cummings, 2018, The Journal of pathology.

Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study

R. Glasspool, S. Leeson, C. Fotopoulou, 2022, Cancers.

Stratification of Length of Stay Prediction following Surgical Cytoreduction in Advanced High-Grade Serous Ovarian Cancer Patients Using Artificial Intelligence; the Leeds L-AI-OS Score

G. Theophilou, R. Hutson, D. Nugent, 2022, Current oncology.

Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01

A. Perkins, P. Kenemans, R. Verheijen, 1998, Cancer Immunology, Immunotherapy.

The value of MRI in management of endometrial hyperplasia with atypia

A. Vinturache, R. Hutson, D. Nugent, 2020, World Journal of Surgical Oncology.

Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning

Angeliki V. Katsenou, G. Theophilou, M. Otify, 2021, Cancer control : journal of the Moffitt Cancer Center.

Parenteral nutrition for patients with advanced ovarian malignancy.

D. Jayne, T. Broadhead, B. Madhok, 2011, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

SOCQER-2 Study: Preliminary analysis of multicentre recruitment after surgery in advanced ovarian cancer

S. Leeson, C. Fotopoulou, C. Cummins, 2016 .

Machine Learning-Based Risk Prediction of Critical Care Unit Admission for Advanced Stage High Grade Serous Ovarian Cancer Patients Undergoing Cytoreductive Surgery: The Leeds-Natal Score

G. Theophilou, Kássio Michell Gomes de Lima, R. Hutson, 2021, Journal of clinical medicine.

Development of a Novel Intra-Operative Score to Record Diseases’ Anatomic Fingerprints (ANAFI Score) for the Prediction of Complete Cytoreduction in Advanced-Stage Ovarian Cancer by Using Machine Learning and Explainable Artificial Intelligence

G. Theophilou, R. Hutson, D. Nugent, 2023, Cancers.

Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis

G. Theophilou, R. Hutson, T. Broadhead, 2023, Cancers.

Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications

G. Theophilou, R. Hutson, T. Broadhead, 2023, Journal of Ovarian Research.